In addition, as studies have progressed, it has been demonstrated that patients are at increased risk of secondary malignancies such as acute myeloid leukemia and myelodysplastic syndromes following G-CSF administration [30]. The gene discussed is CSF3; the disease is myelodysplastic syndrome.